Robert Noecker, MD
Ophthalmology · Pittsburgh, PANPI 1588638217
Payments from drug & device makers
Across 900 payments — averaging $704.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$313K
- Alcon$108K
- Glaukos Corporation$44K
- Novartis$36K
- Iridex Corporation$26K
- Microsurgical Technology, Inc.$23K
- plus $84K from 25 others
What the payments were for
- Consulting fees$217,99034%
- Speaking & faculty fees$318,78850%
- Grants$1500%
- Travel & lodging$53,2688%
- Food & beverage$25,6154%
- Education$16,4503%
- Gifts$900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 430 | $313,118 |
| Alcon | 109 | $108,218 |
| Glaukos Corporation | 45 | $43,566 |
| Novartis | 43 | $36,039 |
| Iridex Corporation | 8 | $26,250 |
| Microsurgical Technology, Inc. | 7 | $22,685 |
| Sight Sciences, Inc. | 42 | $19,719 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 26 | $17,684 |
| Beaver-visitec International, Inc. | 2 | $16,578 |
| Kala Pharmaceuticals, Inc. | 36 | $10,683 |
| Nova Eye, Inc. | 6 | $7,797 |
| Ivantis, Inc | 8 | $4,366 |
| NEW World Medical,inc. | 9 | $2,606 |
| Thea Pharma Inc. | 4 | $2,005 |
| Sun Pharmaceutical Industries Inc. | 36 | $582 |
| Bausch & Lomb Americas Inc. | 24 | $339 |
| Oyster Point Pharma, Inc. | 10 | $274 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $235 |
| Rayner Intraocular Lenses Limited | 9 | $190 |
| Ocular Therapeutix, Inc. | 9 | $158 |
| Aerie Pharmaceuticals, Inc. | 7 | $153 |
| Tarsus Pharmaceuticals, Inc. | 6 | $149 |
| Rxsight Inc | 4 | $144 |
| Biotissue Holdings Inc. | 4 | $137 |
| Dompe US, Inc. | 2 | $43 |
| Astellas Pharma US Inc | 1 | $35 |
| Harrow Eye, LLC | 2 | $32 |
| Amgen | 1 | $21 |
| Omeros Corporation | 1 | $18 |
| Shire North American Group Inc | 1 | $15 |
| Alcon Research LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$147,551
- DURYSTA$104,950
- Hydrus Microstent$90,156
- LUMIGAN$50,205
- COMBIGAN$25,242
- VYZULTA$17,339
- iDose$17,125
- EYSUVIS$16,343
- Voyager DSLT$15,253
- TRAVATAN Z$15,004
- OMNI(R) SURGICAL SYSTEM (US)$10,676
- OMNI$8,372
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$7,600
- ALPHAGAN P$7,095
- DUREZOL$6,391
- Hydrus$4,125
- SIMBRINZA$2,746
- Ahmed Glaucoma Valve$2,529
- Kahook Dual Blade$2,529
- IYUZEH$1,959
How this compares
$633,850 in reported general payments places this provider in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 93 | $110,530 |
| LumiganBimatoprost | 146 | $85,936 |
| CequaCyclosporine | 36 | $50,521 |
| Prednisolone Acetate | 982 | $37,080 |
| EysuvisLoteprednol Etabonate | 69 | $34,330 |
| XiidraLifitegrast | 24 | $33,561 |
| ProlensaBromfenac Sodium | 41 | $17,208 |
| CombiganBrimonidine Tartrate/Timolol | 42 | $16,965 |
| RocklatanNetarsudil Mesylat/Latanoprost | 33 | $16,740 |
| VyzultaLatanoprostene Bunod | 26 | $14,766 |
| MieboPerfluorohexyloctane/Pf | 20 | $14,729 |
| Cyclosporine | 20 | $11,180 |
| Ketorolac Tromethamine | 550 | $11,030 |
| Ofloxacin | 761 | $9,940 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 37 | $9,291 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $313,118 | $222,440313 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $339 | $63,05670 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $582 | $50,52136 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $10,683 | $34,33069 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $17,684 | $23,08781 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $153 | $16,74033 claims |
| AlconSimbrinza | $108,218 | $9,29137 claims |
| NovartisTravatan Z | $36,039 | $5,94413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Pittsburgh
- Francis MahPittsburgh$1.2M
- Srinivas KondapalliPittsburgh$215K
- Deepinder DhaliwalPittsburgh$170K
- Deval ParanjpePittsburgh$121K
- Ian ConnerPittsburgh$103K
- Vishal JhanjiPittsburgh$80K
- David AlmeidaErie$6.3M
- William ChristieCranberry Township$5.2M
- Carl RegilloPlymouth Meeting$3.2M
- Erik KrugerKingston$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.